These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15365083)

  • 1. Exemestane following tamoxifen in postmenopausal women with primary breast cancer.
    Mouridsen HT
    J Clin Oncol; 2004 Sep; 22(18):3833-4. PubMed ID: 15365083
    [No Abstract]   [Full Text] [Related]  

  • 2. Exemestane or tamoxifen?
    Ueda M; Toji E; Noda S
    Lancet; 2007 May; 369(9573):1600; author reply 1600-1. PubMed ID: 17499595
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjuvant treatment of breast cancer with exemestane.
    Tanvetyanon T
    N Engl J Med; 2004 Jul; 351(1):100-2; author reply 100-2. PubMed ID: 15237463
    [No Abstract]   [Full Text] [Related]  

  • 4. Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane.
    Gonnelli S; Cadirni A; Caffarelli C; Petrioli R; Montagnani A; Franci MB; Lucani B; Francini G; Nuti R
    Bone; 2007 Jan; 40(1):205-10. PubMed ID: 16904960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial.
    Hadji P; Ziller M; Kieback DG; Menschik T; Kalder M; Kuck J; Hasenburg A
    Breast; 2009 Jun; 18(3):159-64. PubMed ID: 19364653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exemestane is effective for the chemoprevention of breast cancer.
    Barton MK
    CA Cancer J Clin; 2011; 61(6):363-4. PubMed ID: 21898372
    [No Abstract]   [Full Text] [Related]  

  • 7. Exemestane: a novel aromatase inactivator for breast cancer.
    Jones SA; Jones SE
    Clin Breast Cancer; 2000 Oct; 1(3):211-6. PubMed ID: 11899645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer.
    Fallowfield LJ; Bliss JM; Porter LS; Price MH; Snowdon CF; Jones SE; Coombes RC; Hall E
    J Clin Oncol; 2006 Feb; 24(6):910-7. PubMed ID: 16484701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exemestane: new preparation. No tangible advance in metastatic breast cancer after tamoxifen failure.
    Prescrire Int; 2001 Aug; 10(54):108-9. PubMed ID: 11718178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.
    Coleman RE; Banks LM; Girgis SI; Kilburn LS; Vrdoljak E; Fox J; Cawthorn SJ; Patel A; Snowdon CF; Hall E; Bliss JM; Coombes RC;
    Lancet Oncol; 2007 Feb; 8(2):119-27. PubMed ID: 17267326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer: some reasons to be hopeful.
    Lancet; 2007 Feb; 369(9561):531. PubMed ID: 17307079
    [No Abstract]   [Full Text] [Related]  

  • 12. Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study.
    Coleman RE; Banks LM; Girgis SI; Vrdoljak E; Fox J; Cawthorn SJ; Patel A; Bliss JM; Coombes RC; Kilburn LS
    Breast Cancer Res Treat; 2010 Nov; 124(1):153-61. PubMed ID: 20730486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of exemestane in the Intergroup Exemestane Study.
    Coombes RC; Bliss JM; Hall E
    J Clin Oncol; 2005 May; 23(13):3171-2. PubMed ID: 15860896
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of aromatase inactivators in the treatment of breast cancer.
    Lønning PE
    Int J Clin Oncol; 2002 Aug; 7(4):265-70. PubMed ID: 12202980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching to aromatase inhibitors in early breast cancer.
    Boccardo F; Rubagotti A
    Lancet; 2007 Feb; 369(9561):533-5. PubMed ID: 17307082
    [No Abstract]   [Full Text] [Related]  

  • 17. Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer.
    Love RR; Hutson PR; Havighurst TC; Cleary JF
    Clin Cancer Res; 2005 Feb; 11(4):1500-3. PubMed ID: 15746052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.
    Mamounas EP; Jeong JH; Wickerham DL; Smith RE; Ganz PA; Land SR; Eisen A; Fehrenbacher L; Farrar WB; Atkins JN; Pajon ER; Vogel VG; Kroener JF; Hutchins LF; Robidoux A; Hoehn JL; Ingle JN; Geyer CE; Costantino JP; Wolmark N
    J Clin Oncol; 2008 Apr; 26(12):1965-71. PubMed ID: 18332472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary data from ongoing adjuvant aromatase inhibitor trials.
    Goss PE
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4397s-4401s; discussion 4411s-4412s. PubMed ID: 11916231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
    Morandi P; Rouzier R; Altundag K; Buzdar AU; Theriault RL; Hortobagyi G
    Cancer; 2004 Oct; 101(7):1482-9. PubMed ID: 15378476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.